|Year : 2022 | Volume
| Issue : 1 | Page : 88-91
Headache incidence and characteristics in COVID-19 patients: A hospital-based study
Manisha Sharma, Bindu Menon
Department of Neurology, Apollo Speciality Hospital, Pinakini Nagar, Nellore, Andhra Pradesh, India
|Date of Submission||22-Mar-2021|
|Date of Acceptance||25-Aug-2021|
|Date of Web Publication||29-Nov-2021|
Department of neurology, Apollo Speciality hospital, Pinakini Nagar, Nellore - 524 004, Andhra Pradesh
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Background: Headache is one of the commonly reported symptoms of coronavirus disease-2019 (COVID-19) illness. A number of studies have been done so far focusing on headache associated with COVID-19 with variable incidence and characteristics. Material and Methods: This study is a prospective study conducted on 120 patients with confirmed COVID-19 illness. Critically ill and ventilated patients were excluded. Demographic data, COVID illness symptom profile, headache characteristics were documented. Patients were followed up at 2 weeks and 4 weeks. For the statistical analysis, Statistical Package for the Social Sciences (SPSS), version 24.0 was used. Results: 120 COVID-19 positive cases were included in the study with a mean age of 54.59 ± 14.89 years (range 21-84 years) with male-to-female ratio of 3:2. 78.33% (94) of patients had various comorbidities. 43.33% (52) cases were diabetic. The presenting symptoms were fever (65%), cough (53.33%), shortness of breath (35%) and myalgia (31.66%). 26 (21.66%) patients reported headache during the COVID illness. 18 (15%) cases had headache attributed as secondary to COVID-19 illness. Out of them, 12 cases were new onset with no past history of headache and 6 cases had a significant change in previous headache episodes. COVID-19 illness precipitated headache episodes similar to past headache type in 8 cases. Headache was the presenting symptom in 8 (6.66%) patients with COVID-19 being detected in the regular hospital screening protocol. Conclusion: Headache was a common symptom in COVID-19 patients. New onset headaches or change in past headache type in patients in the setting of ongoing pandemic should be screened for COVID-19.
Keywords: COVID-19, headache, pandemic
|How to cite this article:|
Sharma M, Menon B. Headache incidence and characteristics in COVID-19 patients: A hospital-based study. Ann Indian Acad Neurol 2022;25:88-91
| Introduction|| |
The novel coronavirus (SARS-CoV-2; 2019-nCoV; COVID-19) pandemic has emerged as a global crisis in the early 2020. The most prevalent symptoms reported were fever (78%), cough (57%) and fatigue (31%). Headache is one of the common neurologic manifestations in COVID-19 though it is frequently neglected. Various studies conducted so far showed incidence of headache ranging from 6.5% to as high as 70.3%. There is a paucity of literature with special emphasis on headache in COVID illness with highly variable results in already published research. We aimed to determine the incidence of secondary headache due to COVID-19 illness, to describe its characteristics and temporal relation of headache with other symptoms.
| Material and Methods|| |
This study was a prospective cohort study conducted in a superspeciality hospital from south India, from June 2020 to December 2020. Patients with confirmed COVID-19 illness by COVID-19 reverse transcription polymerase chain reaction (RT-PCR) were included in the study. Ethics committee approval taken dated 14th May 2020. Critically ill patients with dyspnoea, hypoxia, altered sensorium, hemodynamic instability, and on ventilator support who were unable to give history were excluded from the study. All cases were evaluated for headache by a neurologist in personal protection equipment (PPE). COVID-19 hospital safety protocol was followed for each patient. To limit the duration of exposure, demographic information was retrieved telephonically via the patient's hospital room intercom connection. Patient's demographic profile, COVID illness symptomatology, headache characteristics including location, type, severity on visual analogue scale, frequency, duration, aggravating and relieving factors were documented on a proforma. Special emphasis was given on past history of headache and whether the present headache episode was same or different from past to determine new onset of headache. Secondary headache due to COVID-19 illness has included 1) a new-onset headache occurring for the first time in close temporal relation to COVID-19 illness irrespective of its characteristics of a primary headache, 2) a pre-existing primary headache made significantly worse (usually meaning a twofold or greater increase in frequency and/or severity) in close temporal relation to COVID-19 illness. All patients with a positive history of headache were followed for a period of 4 weeks telephonically after discharge from hospital. Calls were made at 2 weeks and 4 weeks. For the statistical analysis, Statistical Package for the Social Sciences (SPSS), version 24.0 was used and statistics included percentage, mean and standard deviation.
| Observations|| |
From June 2020 to December 2020, the hospital received 175 COVID-positive cases. 55 critically ill patients were excluded from the study. 120 COVID-19 positive cases were enrolled with a mean age of 54.59 ± 14.89 years (range 21 -84 years) and male-to-female ratio of 3:2. The detailed demographic profile and COVID symptomatology has been shown in [Table 1]. The average COVID-19 reporting and data system (CO-RADS) score was 4.33 (range 0–5) with mean chest CT severity index of 8.03 (range 0-20). Comorbidities like hypertension, diabetes, coronary artery disease, obstructive lung disease, chronic kidney disease were present in 78.33% (94) of cases. 43.33% (52) cases were diabetic. There were three or more than three comorbidities in 11.66% (14) cases. One patient had newly retroviral state positive. The common symptoms were fever (65%), cough (53.33%), shortness of breath (35%), myalgia (31.66%) followed by headache (21.66%). Sore throat, diarrhoea, loss of smell/taste, and fatigue were less commonly reported. None of the patients had altered sensorium, neck rigidity or focal neurological deficit. 5% of cases were on oxygen support.
Out of 120 COVID-positive cases, 26 (21.66%) reported headache during COVID illness. Out of these, 12 cases reported new-onset headache without any past history of headache. Fourteen cases had a past history of headache (7 migraine headache, 2 tension-type headache, 2 sinusitis, 1 post-traumatic headache, 2 nonspecific headache types). Among these 14, 6 cases reported a change in their character of headache from their regular headaches. So overall, secondary headache due to COVID-19 illness was reported in 18 (15%) cases and in other 8 cases, COVID illness precipitated the headache episode of past headache type [Figure 1].
|Figure 1: Flow chart showing study enrollment and headache classification|
Click here to view
Characteristics of secondary headache in 18 (15%) cases are given in [Table 2]. Out of 18 secondary headache cases, 8 cases (6.66%) had headache as the first presenting symptom followed by fever (1-4 days interval range) and cough (1–8 days interval range). Location of headache was mostly bilateral in the temporal and frontal region. Headache was intermittent in all cases with variable duration of 30 minutes to 3 days. Onset was sudden as well as gradual with evening predilection. Headache was mild (mean visual analogue scale 2.76) vague dull aching type in most of the cases. The associated features reported were nausea, vomiting, phonophobia and photophobia. Cough was a common aggravating factor followed by stress and fever. The relieving factors reported were sleep and hot beverages. Brain imaging was not done in any case. All 18 patients were followed up telephonically for the next 1 month after discharge at 2 weeks and 4 weeks. There was complete headache relief in 8 out of 18 cases within hospital stay. Rest 10 cases were on painkillers when required and recovered within an average duration of 8.33 days after discharge. As per the international classification of headache disorders 3rd edition (ICHD-3b), only 5 out of 18 cases fit into a classical headache phenotype. 3 cases had tension-type headache and 2 cases had migraine features. Rest 13 patients were not classified.
| Discussion|| |
Headache attributed to infection (bacterial, viral, fungal, parasitic) is one of the important subgroup in the secondary headache category as per ICHD-3b. Intracranial infection as meningitis or meningoencephalitis as well as systemic infection can lead to headache. There should be a temporal relationship between headache and infection onset to establish the causal link.
Pathophysiologically, intracranial infections cause headache via direct meningeal infiltration, inflammatory effects of the products of bacteria and by inflammatory mediators. Whereas systemic infections like influenza cause irritation of pericranial or intracranial pain-sensitive structures by direct infiltration, release of endotoxins or the immune response of inflammatory mediators. Some organisms may trigger brainstem nuclei with the end result of neurogenic inflammation and headache. COVID encephalitis has been reported in 6% of cases. In this study, none of the patients had meningoencephalitis. All new-onset headaches or headaches with a significant change in past headache type had been attributed to systemic COVID illness in view of presence of definite temporal relation between the two.
In COVID-19 illness, headache has been reported in the category of “less common symptoms'' among the most prevalent ones like fever, fatigue, dry cough, myalgia and dyspnoea which is consistent with this study. But it was alarming that 8 out of 18 new-onset headache cases had headache as the first and only manifestation of COVID illness. Fever and cough followed the headache by a duration of 4- 8 days. In cases, headache preceded fever by 4 days and cough by 8 days. So in this pandemic era, any new-onset headache warrants low threshold for testing for COVID-19 resulting in early diagnosis before respiratory involvement to reduce the spread of infection.
Al-Hashel et al. reported 59.6% increase in migraine frequency and 64.1% increase in migraine severity during COVID era as compared to pre-pandemic period though only 4% migraine cases had COVID illness. The reasons are independent of COVID illness and multifactorial like poor follow up with neurologist, poor drug compliance, analgesic overuse, cancellation of botox sessions, poor sleep, anxiety and depression., Even mask-associated 'denovo' headache has been reported in 51.6 percent of healthcare workers. So attributing COVID-19 as the causative factor to all headache types in COVID illness is probably not justified. Clinicians need to take the headache symptom in a broader perspective and consider other differentials even in the setting of COVID-19 illness. This study specifies that COVID illness-associated headache should be diagnosed in the setting of new-onset headache or change in past headache type in COVID illness with definite temporal relation between the two.
COVID-19 associated headache has been frequently reported as mild to moderate intensity. Uygun et al. 2020 found mild- and moderate-intensity headache in 74.3% vs severe and very severe headache in 25.7% COVID-19 positive patients. Various classical headache phenotypes like migraine or tension-type headache independent of past history of primary headache have been rarely reported except few studies., Cough was identified as a major aggravating factor. Such cases need neuroimaging to rule out possible intracranial lesions like Arnold-Chiari malformation type 1, spontaneous intracranial hypotension, carotid or vertebrobasilar diseases, middle cranial fossa or posterior fossa tumours, midbrain cyst, basilar impression, platybasia, subdural haematoma, cerebral aneurysms and reversible cerebral vasoconstriction syndrome. In this study, MRI brain was not done in any patient despite sudden onset in 8 cases and aggravation by cough in 3 cases. Because headache intensity was low on visual analogue scale in most of the cases with no focal neurological deficit on examination. There was satisfactory response to symptomatic treatment. COVID protocols for imaging in hospital also increased the threshold for MRI.
Various clinical correlates have been documented so far with headache in COVID illness. Headache has been commonly reported with anosmia/ageusia, younger age, fewer comorbidities and reduced mortality, as well as with low levels of C-reactive protein, mild acute respiratory distress syndrome, oropharyngeal symptoms, female sex and fever. Less number of positive headache patients in this study had limited us to show any particular pattern of COVID-19 associated headache, correlation of headache with various variables and effect of headache on prognosis. The second limitation of this study was inability to get brain imaging in all patients. It would have helped to rule out other secondary causes specially in current situation where cerebral thromboembolic events like ischemic stroke and cerebral venous sinus thrombosis are being frequently reported in association with COVID-19 illness. Moreover, exclusion of critically ill on ventilator patients limited us from reporting true incidence of headache in COVID illness. More data in the future will help us to better understand the headache pattern in COVID-19 patients.
| Conclusion|| |
Aetiology of headache during COVID pandemic can be multifactorial. But new-onset headache or change in past headache type should be considered a symptom and the threshold for COVID screening should be low in such patients even in the absence of fever and cough. Secondary headache due to COVID illness can be described as either sudden or gradual onset, mild vague aching type, mostly in temporal or frontal location, bilateral, intermittent with variable duration and evening predilection, commonly aggravated by cough and relieved by sleep.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, et al
. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries. PLoS One 2020;15:e0234765.
Tian S, Hub N, Lou J, Chen K, Kang X, Xiang Z, et al
. Characteristics of COVID-19 infection in Beijing. J Infect 2020;80:401-6.
Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, et al
. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease. J Intern Med 2020;288:335-44.
Olesen J, Dodick D, Ducros A, Evers S, First M, Goadsby P, et al
. The International Classification of Headache Disorders, 3rd
edition (ICHD-3). Cephalalgia 2018;38:1-121. doi: 10.1177/0333102417738202.
Kahn K. Chapter 2: Headache due to systemic disease. In: Neurological Disorders due to Systemic Disease. 1st
ed. Oxford: Blackwell Publishing Ltd; 2013. p. 3-28. doi: 10.1002/9781118414019.ch2.
Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al
. Neurological associations of COVID-19. Lancet Neurol 2020;19:767-83.
Chatterjee P, Nagi N, Agarwal A, Das B, Banerjee S, Sarkar S, et al
. The 2019 novel coronavirus disease (COVID-19) pandemic: A review of the current evidence. Indian J Med Res 2020;151:147-59.
] [Full text]
Islam MA, Alam SS, Kundu S, Hossan T, Kamal MA, Cavestro C. Prevalence of headache in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of 14,275 patients. Front Neurol 2020;11:562634. doi: 10.3389/fneur. 2020.562634.
Al-Hashel JY, Ismail II. Impact of coronavirus disease 2019 (COVID-19) pandemic on patients with migraine: A web-based survey study. J Headache Pain 2020;21:115.
Ramirez-Moreno JM, Ceberino D, Gonzalez Plata A
, Rebollo B, Macias Sedas P, Hariramani R, et al
. Mask-associated 'de novo' headache in healthcare workers during the COVID-19 pandemic. Occup Environ Med 2020;1-7. doi: 10.1136/oemed-2020-106956.
Caronna E, Ballvé A, Llauradó A, Gallardo VJ, Ariton DM, Lallana S, et al
. Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. Cephalalgia 2020;40:1410-21.
Uygun O, Ertas M, Ekizoglu E, Bolay H, Ozge A, Kocasoy Orhan E, et al
. Headache characteristics in COVID-19 pandemic-a survey study. J Headache Pain 2020;21:121.
Goërtz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, et al
. Persistent symptoms 3 months after a SARS-CoV-2 infection: The post-COVID-19 syndrome? ERJ Open Res 2020;6. doi: 10.1183/23120541.00542-2020.
Gonzalez-Martinez A, Fanjul V, Ramos C, Serrano Ballesteros J, Bustamante M, Villa Martí A, et al
. Headache during SARS-CoV-2 infection as an early symptom associated with a more benign course of disease: A case-control study. Eur J Neurol 2021. doi: 10.1111/ene. 14718.
Trigo J, Garcia-Azorin D, Planchuelo-Gomez A, Martinez-Pias E, Talavera B, Hernandez-Perez I, et al
. Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: A retrospective cohort study. J Headache Pain 2020;21:94.
[Table 1], [Table 2]